Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Merck Posts Report Revealing Average Price Hikes for Drugs in U.S.

By Ryan Bushey | February 2, 2017

Another drug company unveiled a new strategy for dealing with the drug pricing debate.

Merck & Co. published a report on January 27th called the Pricing Action Transparency Report, which provided details on the average price increase for drugs and vaccines in its portfolio between 2010 and 2016.

The document indicated the average list price change for its product offerings started at 7.4 percent in 2010 hitting a high of 10.5 percent in 2014. Other years saw the list price change hover between 9.2 and 9.8 percent.

Furthermore, the report indicated the average net price change based on wholesale acquisitions minus discounts and rebates varied from 3.4 percent to 6.2 percent whereas average discounts reached 40.9 percent, according to FiercePharma.

Robert McMahon, the president of Merck’s U.S. market, told the Wall Street Journal the company posted these figures because they felt they needed to provide greater transparency into list and net prices since price increases have become an important issue.

Merck didn’t highlight specific drugs in the report, but this announcement follows other drug-makers looking for different approaches to address criticism from the public and politicians on both sides of the aisle over large price hikes for important drugs.

Firms like AbbVie, Takeda, Novo Nordisk, and Allergan have pledged to limit any price raises to annual single-digit percentages while Johnson & Johnson will release their own transparency report sometime this month with a layout similar to Merck’s.

You can view Merck’s chart below. The company plans on updating these numbers every January going forward.

Source: Merck


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE